Ron Peters in conversation with Ulf Landmesser
RESPONSE: Effect of a nurse coordinated prevention program on cardiovascular risk after an acute coronary syndrome: Main results of the RESPONSE trial.

Sanjit Jolly in conversation with Thomas Lüscher
FUTURA OASIS 8 : A randomised trial comparing two regimens of adjunctive intravenous unfractionated heparin during PCI in high-risk patients with non-STE-ACS treated with fondaparinux.

Jens Nielsen In conversation with Thomas Lüscher
DANPACE: The Danish multicentre randomised trial on single lead atrial versus dual chamber pacing in sick sinus syndrome.

John McMurray In conversation with Frank Ruschitzka
TREAT: Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin) Therapy.

Andreas Goette In conversation with Bernard Gersh
ANTIPAF: Angiotensin II-antagonist in paroxysmal atrial fibrillation trial.

Stefanie Schulz in conversation with Ulf Landmesser
ISAR REACT 3A: A trial of reduced dose of unfractionated heparin in patients undergoing percutaneous coronary interventions.

Sunil Rao in conversation with Thomas Lüscher
INNOVATE PCI: A Phase II Safety and Efficacy Study of PRT060128 (Elinogrel), a Novel Intravenous and Oral P2Y12 Inhibtor in Non-Urgent PCI.

Stuart Connolly in conversation with Thomas Lüscher
AVERROES: Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Strokes.

Adriaan Voors in a conversation with Thomas Lüscher
HEBE III: A single dose of erhthropoietin in ST-elevation myocardial infarction.

Bertram Pitt in conversation with Frank Ruschitzka
PEARL HF: Multicentre, randomized, double-blind, placebo-controlled, parallel-group, mulitple-dose study to evaluate the effects of RLY5016 in heart failure patients.